Hydroxychloroquine And Azithromycin As A Treatment Of Coronavirus

A recent paper reported an inhibitor effect of remdesivir (a new antiviral drug) and
chloroquine (an old antimalarial drug) on the growth of SARS-CoV-2 in vitro, [8] and an
early clinical trial conducted in COVID-19 Chinese patients showed that chloroquine had a
significant effect, both in terms of clinical outcome and viral clearance, when comparing to
controls groups [9,10]. Chinese experts recommend that patients diagnosed as mild, moderate
and severe cases of COVID-19 pneumonia and without contraindications to chloroquine, be
treated with 500 mg chloroquine twice a day for ten days

Hydroxychloroquine (an analog of chloroquine) has been demonstrated to have an anti-
SARS-CoV activity in vitro [12]. Hydroxychloroquine clinical safety profile is better than that

of chloroquine (during long-term use) and allows a higher daily dose [13] and has fewer.

Read full details here: Hydroxychloroquine and azithromycin as a treatment of COVID-19